Synovics Pharmaceuticals Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Jyotindra Gange

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	16.6yrs
CEO ownership	n/a
Management average tenure	no data
Board average tenure	16.8yrs

Recent management updates

No updates

Recent updates

No updates

CEO

Jyotindra Gange (75 yo)

16.6yrs

Tenure

Mr. Jyotindra R. Gange has been an Interim Principal Executive Officer at Synovics Pharmaceuticals, Inc. since July 3, 2008. Mr. Gange serves as Chief Financial Officer of Maneesh Pharmaceuticals, Ltd. Pre...

Board Members

Name	Position	Tenure	Compensation	Ownership
Jyotindra Gange	Interim Principal Executive Officer & Director	16.8yrs	no data	no data
John Palmer	Chairman of InCon Technologies Inc.& Incon International Ltd. & CEO of InCon Technologies Inc	no data	no data	no data
Vinay Sapte	Director	16.8yrs	no data	no data
Harcharan Singh	Director	16.8yrs	US$491.11k	no data
Maneesh Sapte	Director	16.8yrs	no data	no data

16.8yrs

Average Tenure

74yo

Average Age

Experienced Board: SYVC's board of directors are seasoned and experienced ( 16.8 years average tenure).

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/02/23 06:50
End of Day Share Price	2024/12/03 00:00
Earnings	2009/07/31
Annual Earnings	2008/10/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Synovics Pharmaceuticals, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.